Date:- 30 September, 2019

  • A 15M€ European granted consortium led by Laurence Zitvogel from Gustave Roussy in Villejuif.
  • HalioDx task is to link biomarkers discoveries achieved in the consortium to bedside applications.

HalioDx SAS, an immuno-oncology company pioneering the immunological diagnosis of cancers, today described its participation to the ONCOBIOME consortium.

The ONCOBIOME project (€ 15 million) aim is to determine the relationship between intestinal microbial signatures (GOMS) and the response, resistance and toxicity induced by treatments in breast, colon, lung and skin cancers. The program should result in multi-pamametric diagnostic tests for prognostic and prediction of resistance to immunotherapy. This project is being supported by the European Union Horizon fund (H2020) and is led by Prof. Laurence Zitvogel from Gustave Roussy (Villejuif).

HalioDx will apply its expertise in diagnostic research and development and combine its Immunoscore®solutions with other biomarkers including microbiome signatures to highlight relationships between the intestinal metagenome makeup of patients and their tumor biology. To achieve this goal, HalioDx will analyse samples from 1000 cancer patients originating from retrospective and prospective studies including immunotherapy-based cohorts. Additionally, HalioDx will industrialize highlighted predictive GOMS as a clinical research tool for subsequent validation and diagnostic tests development. Vincent FERT, CEO of HalioDx comments:We are excited to be the diagnostic partner of this ambitious European program gathering leading scientific experts in the field. The link between cancer and intestinal microbiota is one of the most exciting new fields in clinical oncology. Immunoscore®, as a mature and robust solution, can help to interrogate and explore the impact of the microbiota on cancer development. This project reinforces our ambition to deliver unique diagnostic tests that could impact positively cancer treatment efficacy and safety.



Related Files